<DOC>
	<DOC>NCT00994760</DOC>
	<brief_summary>The aim of the study was to evaluate the safety and efficacy of intranasal fentanyl spray in cancer patients over four weeks, especially during cancer-related breakthrough pain (BTP) attacks. The fentanyl spray was applied into the nose by a metered-spray device. The study was to provide further data on pharmacoeconomic efficiency of intranasal fentanyl spray.</brief_summary>
	<brief_title>Efficacy and Tolerability of Intranasal Fentanyl Spray for the Treatment of Breakthrough Pain in Cancer Patients Older Than 18 Years</brief_title>
	<detailed_description />
	<mesh_term>Breakthrough Pain</mesh_term>
	<mesh_term>Fentanyl</mesh_term>
	<criteria>Inclusion criteria: decision to start treatment with intranasal fentanyl spray written informed consent Exclusion criteria: criteria as defined in the Summary of Product Characteristics (Fachinformation Chapter 4.3)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>intranasal fentanyl spray</keyword>
</DOC>